Hemophagocytic lymphohistiocytosis caused by multiple infections during primary chemotherapy for pediatric acute lymphoblastic leukemia: a case report.

IF 5.7 2区 医学 Q1 IMMUNOLOGY Frontiers in Immunology Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI:10.3389/fimmu.2024.1438378
Yaning Ao, Yusheng Huang, Xiaobo Zhou, Jiawen Li, Qing Zhang, Sujun Wu, Ying Fu, Jinfeng Zhang
{"title":"Hemophagocytic lymphohistiocytosis caused by multiple infections during primary chemotherapy for pediatric acute lymphoblastic leukemia: a case report.","authors":"Yaning Ao, Yusheng Huang, Xiaobo Zhou, Jiawen Li, Qing Zhang, Sujun Wu, Ying Fu, Jinfeng Zhang","doi":"10.3389/fimmu.2024.1438378","DOIUrl":null,"url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that occurs as a consequence of immune dysregulation. HLH can be primary (familial or non-familial) or secondary to infection, autoimmune disease or malignancy. Malignancy-associated HLH is often accompanied by hematologic and lymphoid neoplasms. This report describes the case of a 3-year-old girl with an initial diagnosis of acute lymphoblastic leukemia who subsequently developed HLH during primary chemotherapy. She was admitted with a pulmonary infection, and initial blood tests showed thrombocytopenia and anemia. Whole-exome sequencing of gene and whole transcriptome RNA sequencing data indicated mutations of <i>UNC13D</i>. The hospital course was complicated by multiple infections, altered mental status and acute respiratory distress syndrome. HLH secondary to multiple infections that achieved remission following targeted therapy with ruxolitinib, in conjunction with corticosteroids and other complementary treatments. This report provides a synopsis of the diagnostic and treatment procedures implemented in this case.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"15 ","pages":"1438378"},"PeriodicalIF":5.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2024.1438378","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that occurs as a consequence of immune dysregulation. HLH can be primary (familial or non-familial) or secondary to infection, autoimmune disease or malignancy. Malignancy-associated HLH is often accompanied by hematologic and lymphoid neoplasms. This report describes the case of a 3-year-old girl with an initial diagnosis of acute lymphoblastic leukemia who subsequently developed HLH during primary chemotherapy. She was admitted with a pulmonary infection, and initial blood tests showed thrombocytopenia and anemia. Whole-exome sequencing of gene and whole transcriptome RNA sequencing data indicated mutations of UNC13D. The hospital course was complicated by multiple infections, altered mental status and acute respiratory distress syndrome. HLH secondary to multiple infections that achieved remission following targeted therapy with ruxolitinib, in conjunction with corticosteroids and other complementary treatments. This report provides a synopsis of the diagnostic and treatment procedures implemented in this case.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小儿急性淋巴细胞白血病初次化疗期间多次感染引起的嗜血细胞淋巴组织细胞增多症:病例报告。
嗜血细胞淋巴组织细胞增多症(HLH)是一种因免疫调节失调而导致的高炎症性疾病,可危及生命。嗜血细胞淋巴细胞增多症可以是原发性(家族性或非家族性),也可以是继发于感染、自身免疫性疾病或恶性肿瘤。恶性肿瘤相关的 HLH 通常伴有血液肿瘤和淋巴肿瘤。本报告描述了一例 3 岁女童的病例,她最初被诊断为急性淋巴细胞白血病,随后在接受原发性化疗期间出现 HLH。她因肺部感染入院,最初的血液检查显示血小板减少和贫血。基因全外显子组测序和全转录组 RNA 测序数据显示 UNC13D 发生了突变。多次感染、精神状态改变和急性呼吸窘迫综合征使住院过程变得复杂。继发于多种感染的 HLH,在接受 ruxolitinib 靶向治疗、皮质类固醇和其他辅助治疗后病情得到缓解。本报告概述了该病例的诊断和治疗过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.80
自引率
11.00%
发文量
7153
审稿时长
14 weeks
期刊介绍: Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.
期刊最新文献
Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Personalized cancer vaccine design using AI-powered technologies. Regulatory T cells and macrophages in atherosclerosis: from mechanisms to clinical significance. Retraction: Baricitinib protects mice from sepsis-induced cardiac dysfunction and multiple-organ failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1